The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising
Raoul Manalac, MD, a board-certified Internal Medicine Physician with Ro
Palioura E, Diamanti-Kandarakis E
Gic ng cht lng, tinh thn khe, tuy nhin s c 1 giai on hay bun ng
Carotenemia does not cause any harm, but it can lead to a false jaundice diagnosis
Feedback from interested parties has indicated that PCPs are best equipped to conduct HRSN screenings and may have established relationships with community resources to address identified needs